3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Status
Completed
5
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Muscle Invasive Bladder Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
86
Cyclophosphamide
75
Nivolumab
55
Specimen Handling
49
fludarabine
48
Magnetic Resonance Spectroscopy
44
Carboplatin
41
Biopsy
39
Radiotherapy
32
fludarabine phosphate
29
Gemcitabine
28
venetoclax
27
atezolizumab
26
Paclitaxel
26
Ipilimumab
26
Radiation
22
Dexamethasone
22
Cisplatin
22
Radiosurgery
21
durvalumab
20
Rituximab
20
Lenalidomide
19
Temozolomide
17
Bevacizumab
17
Pemetrexed
15
Decitabine
15
Cytarabine
15
130-nm albumin-bound paclitaxel
15
palbociclib
14
ibrutinib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Active not recruiting
×
danvatirsen
×
Clear all
NCT03819465
2026-05-12
MAGELLAN
AstraZeneca
Phase 1
Active not recruiting
175 enrolled
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled